fluorouracil has been researched along with Liver Cirrhosis in 58 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 9.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| "Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 9.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
| "The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 7.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 7.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 7.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 7.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 7.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 5.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| "The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 5.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 5.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 5.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| "We report a case of HCC with liver cirrhosis and lung metastases who had been treated successfully by combination chemotherapy of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha)." | 5.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 5.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| "Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 5.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
| "Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system." | 3.81 | VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015) |
| " However, it has also been reported that 5-fluorouracil (5-FU) exacerbates liver damage in patients with liver cirrhosis (LC)." | 3.76 | Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Shinohara, M; Shizawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2010) |
| "The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 3.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 3.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 3.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 3.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 3.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined." | 3.66 | [Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982) |
| "The development of liver cancer is strongly tied with fibrosis and cirrhosis that alters the microenvironmental landscape, especially ECM composition." | 1.72 | Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment. ( Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y, 2022) |
| "Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression." | 1.46 | A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017) |
| "Our results suggest that repeated TACE is safe in selected patients with TIPS." | 1.40 | Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. ( Li, X; Luo, X; Tsauo, J; Wang, X; Wang, Z; Zhang, H; Zhao, H, 2014) |
| "Furthermore pathogenesis of liver fibrosis is not well known." | 1.39 | A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer. ( Jeong, HY; Kang, DY; Kang, GH; Kim, SH; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK, 2013) |
| "The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "With conventional doses, four indices of liver fibrosis focusing on hyaluronate acide (HA), human procollagen type-III (hPC-III), collagen type-IV (IV-C) and transforming growth factor-βl (TGF-β1) were obviously increased postoperative compared with preoperative (P<0." | 1.38 | Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012) |
| "The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 1.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
| "However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear." | 1.35 | Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008) |
| "Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 1.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "Case 1 was a 71-year-old woman with a hepatocellular carcinoma (HCC), 45 mm in diameter, with liver cirrhosis." | 1.34 | [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. ( Hirashita, T; Nakashima, K; Sakai, I; Sakai, M, 2007) |
| "We report a case of HCC with liver cirrhosis and lung metastases who had been treated successfully by combination chemotherapy of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha)." | 1.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 1.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
| "The patient was a 51-year-old male." | 1.32 | [The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient]. ( Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y, 2004) |
| "Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz." | 1.27 | [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985) |
| "Liver cirrhosis was present only in the males (in 50% of them)." | 1.27 | Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. ( Audisio, R; Bignami, P; Bonfanti, G; Bozzetti, F; Colombo, M; Doci, R; Gennari, L, 1988) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 1.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (31.03) | 18.7374 |
| 1990's | 2 (3.45) | 18.2507 |
| 2000's | 15 (25.86) | 29.6817 |
| 2010's | 20 (34.48) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, L | 1 |
| Zhang, Y | 1 |
| Yang, Y | 1 |
| Yan, Q | 1 |
| Ren, J | 1 |
| Luo, J | 1 |
| Tiu, YC | 1 |
| Fang, X | 1 |
| Liu, B | 1 |
| Lam, RHW | 1 |
| Lam, KO | 1 |
| Lee, AW | 1 |
| Guan, XY | 1 |
| Huang, C | 1 |
| Chen, J | 1 |
| Situ, Y | 1 |
| Liu, F | 1 |
| Xu, Y | 1 |
| Yang, G | 1 |
| Guo, Y | 1 |
| Nian, J | 1 |
| Miyauchi, Y | 1 |
| Yasuchika, K | 1 |
| Fukumitsu, K | 1 |
| Ishii, T | 1 |
| Ogiso, S | 1 |
| Minami, T | 1 |
| Kojima, H | 1 |
| Yamaoka, R | 1 |
| Katayama, H | 1 |
| Kawai, T | 1 |
| Yoshitoshi-Uebayashi, EY | 1 |
| Kita, S | 1 |
| Yasuda, K | 1 |
| Sasaki, N | 1 |
| Uemoto, S | 1 |
| Robinson, SM | 1 |
| Mann, J | 1 |
| Vasilaki, A | 1 |
| Mathers, J | 1 |
| Burt, AD | 1 |
| Oakley, F | 1 |
| White, SA | 1 |
| Mann, DA | 1 |
| Nagai, H | 8 |
| Mukozu, T | 2 |
| Kanekawa, T | 3 |
| Matsui, T | 4 |
| Kanayama, M | 6 |
| Wakui, N | 3 |
| Momiyama, K | 5 |
| Ishii, K | 3 |
| Igarashi, Y | 3 |
| Sumino, Y | 8 |
| Kang, GH | 1 |
| Moon, HS | 1 |
| Lee, ES | 1 |
| Kim, SH | 1 |
| Sung, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Lee, HY | 1 |
| Kang, DY | 1 |
| Reddy, SK | 1 |
| Reilly, C | 1 |
| Zhan, M | 1 |
| Mindikoglu, AL | 1 |
| Jiang, Y | 1 |
| Lane, BF | 1 |
| Alexander, HR | 1 |
| Culpepper, WJ | 1 |
| El-Kamary, SS | 1 |
| Battisti, S | 1 |
| Guida, FM | 1 |
| Pagliara, E | 1 |
| Tonini, G | 1 |
| Zobel, BB | 1 |
| Santini, D | 1 |
| Wang, Z | 1 |
| Zhang, H | 1 |
| Zhao, H | 1 |
| Wang, X | 1 |
| Tsauo, J | 1 |
| Luo, X | 1 |
| Li, X | 1 |
| Russolillo, N | 1 |
| Ratti, F | 1 |
| Viganò, L | 1 |
| Langella, S | 1 |
| Cipriani, F | 1 |
| Aldrighetti, L | 1 |
| Ferrero, A | 1 |
| Matsui, D | 2 |
| Ogino, YU | 1 |
| Stremitzer, S | 1 |
| Stift, J | 1 |
| Singh, J | 1 |
| Starlinger, P | 1 |
| Gruenberger, B | 1 |
| Tamandl, D | 1 |
| Gruenberger, T | 1 |
| Mukouzu, T | 1 |
| Shinohara, M | 2 |
| Seo, JH | 1 |
| Song, MJ | 1 |
| Lim, EJ | 1 |
| Chin, R | 1 |
| Nachbur, U | 1 |
| Silke, J | 1 |
| Jia, Z | 1 |
| Angus, PW | 1 |
| Torresi, J | 1 |
| Shizawa, K | 1 |
| Watanabe, M | 2 |
| Iida, K | 1 |
| Coriat, R | 1 |
| Mir, O | 1 |
| Cessot, A | 1 |
| Brezault, C | 1 |
| Ropert, S | 1 |
| Durand, JP | 1 |
| Cacheux, W | 1 |
| Chaussade, S | 1 |
| Goldwasser, F | 1 |
| Takanashi, K | 1 |
| Katsuki, S | 1 |
| Fujita, T | 1 |
| Waga, E | 1 |
| Shimodate, Y | 1 |
| Sasaki, K | 1 |
| Someya, T | 1 |
| Ohno, K | 1 |
| Fujita, M | 1 |
| Li, H | 1 |
| Hu, Y | 1 |
| Li, N | 1 |
| Zhou, Y | 1 |
| Antoniou, E | 1 |
| Mantas, D | 1 |
| Paraskeva, P | 1 |
| Dimitroulis, D | 1 |
| Smyrnis, A | 1 |
| Nikitakis, N | 1 |
| Labadariou, A | 1 |
| Tsavaris, N | 1 |
| Vernicos, P | 1 |
| Kostakis, A | 1 |
| Kong, WD | 1 |
| Cao, JM | 1 |
| Xu, J | 1 |
| Chen, B | 1 |
| Yang, T | 1 |
| Xu, TT | 1 |
| Lu, GM | 1 |
| Li, J | 1 |
| Huang, XE | 1 |
| Patt, YZ | 2 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Brown, TD | 1 |
| Vauthey, JN | 1 |
| Curley, SA | 1 |
| Ellis, LM | 1 |
| Nanashima, A | 1 |
| Tanaka, K | 1 |
| Yamaguchi, H | 1 |
| Shibasaki, S | 1 |
| Morino, S | 1 |
| Yoshinaga, M | 1 |
| Sawai, T | 1 |
| Nakagoe, T | 1 |
| Ayabe, H | 1 |
| Takada, J | 1 |
| Katsuki, Y | 1 |
| Hamada, H | 1 |
| Tsuji, Y | 1 |
| Sugimoto, K | 1 |
| Shiraki, K | 1 |
| Yamanaka, Y | 1 |
| Yamamoto, N | 1 |
| Murata, K | 1 |
| Nakano, T | 1 |
| Lim, TY | 1 |
| Cheong, JY | 1 |
| Cho, SW | 1 |
| Sim, SJ | 1 |
| Kim, JS | 1 |
| Choi, SJ | 1 |
| Choi, JW | 1 |
| Kwon, HC | 1 |
| Lee, KM | 1 |
| Kim, JK | 1 |
| Won, JH | 1 |
| Yoo, BM | 1 |
| Lee, KJ | 1 |
| Hahm, KB | 1 |
| Kim, JH | 1 |
| Shitara, K | 1 |
| Munakata, M | 1 |
| Kudo, T | 1 |
| Muto, O | 1 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 1 |
| Kondo, M | 1 |
| Ishii, E | 1 |
| Yabu, K | 1 |
| Hirashita, T | 1 |
| Nakashima, K | 1 |
| Sakai, M | 1 |
| Sakai, I | 1 |
| Miyaki, D | 1 |
| Higami, K | 1 |
| Ikehara, T | 1 |
| Miki, K | 1 |
| von Delius, S | 1 |
| Lersch, C | 1 |
| Mayr, M | 1 |
| Stock, K | 1 |
| Schulte-Frohlinde, E | 1 |
| Schmid, RM | 1 |
| Eckel, F | 1 |
| Akiharu, W | 1 |
| Higashi, T | 1 |
| Kobayashi, M | 1 |
| Nakatsukasa, H | 1 |
| Fujiwara, M | 1 |
| Shiota, T | 1 |
| Yamauchi, Y | 1 |
| Ito, T | 1 |
| Yamamoto, H | 1 |
| Nagashima, H | 1 |
| Onji, M | 1 |
| Yamashita, Y | 1 |
| Horiike, N | 1 |
| Kanaoka, M | 1 |
| Ohta, Y | 1 |
| Yoshida, T | 1 |
| Hattori, M | 1 |
| Munehisa, T | 1 |
| Tajima, H | 1 |
| Goto, M | 1 |
| Nakata, K | 1 |
| Muro, T | 1 |
| Kawahara, K | 1 |
| Kohno, K | 1 |
| Sato, A | 1 |
| Furukawa, R | 1 |
| Ogino, T | 1 |
| Bismuth, H | 1 |
| Chiche, L | 1 |
| Adam, R | 1 |
| Castaing, D | 1 |
| Stuart, K | 1 |
| Tessitore, J | 1 |
| Huberman, M | 1 |
| Ono, T | 1 |
| Yamanoi, A | 1 |
| Nazmy El Assal, O | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Aguayo, A | 1 |
| Nakada, T | 1 |
| Yamauchi, M | 1 |
| Toda, G | 1 |
| Leung, TW | 1 |
| Tang, AM | 1 |
| Zee, B | 1 |
| Yu, SC | 1 |
| Lai, PB | 1 |
| Lau, WY | 1 |
| Johnson, PJ | 1 |
| Hobara, N | 1 |
| Watanabe, A | 1 |
| Kushnir, IN | 1 |
| Miura, T | 2 |
| Hatta, Y | 1 |
| Endo, Y | 1 |
| Sassa, T | 1 |
| Yoshikawa, N | 1 |
| Hirose, N | 1 |
| Funatomi, H | 1 |
| Taguchi, S | 1 |
| Takenaka, K | 1 |
| Kanematsu, T | 1 |
| Shimada, M | 1 |
| Sugimachi, K | 1 |
| Une, Y | 1 |
| Ito, Y | 1 |
| Ogasawara, K | 1 |
| Nagafuchi, E | 1 |
| Matsuoka, S | 1 |
| Misawa, K | 1 |
| Sato, N | 1 |
| Nakajima, Y | 1 |
| Uchino, J | 1 |
| Mori, M | 1 |
| Hamazaki, K | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Doci, R | 1 |
| Bignami, P | 1 |
| Bozzetti, F | 1 |
| Bonfanti, G | 1 |
| Audisio, R | 1 |
| Colombo, M | 1 |
| Gennari, L | 1 |
| Oguma, S | 1 |
| Sakai, K | 1 |
| Sato, R | 1 |
| Ouchi, K | 1 |
| Owada, Y | 1 |
| Sato, T | 1 |
| Kawata, S | 1 |
| Noda, S | 1 |
| Imai, Y | 1 |
| Tamura, S | 1 |
| Saitoh, R | 1 |
| Miyoshi, S | 1 |
| Minami, Y | 1 |
| Tarui, S | 1 |
| Bessot, M | 1 |
| Duprez, A | 1 |
| Iwamura, K | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Markoff, N | 1 |
| Kagan, AR | 1 |
| Ishida, M | 1 |
| Hatano, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fluorouracil and Liver Cirrhosis
| Article | Year |
|---|---|
Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature.
Topics: Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Liver Cirrhosis; Liver Diseases; Portal Vein; Po | 2023 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
[Ligation of the hepatic artery in the treatment of liver tumors (review of the literature)].
Topics: Adult; Anti-Bacterial Agents; Fluorouracil; Hemangioma; Hepatic Artery; Humans; Ligation; Liver Cirr | 1975 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
4 trials available for fluorouracil and Liver Cirrhosis
| Article | Year |
|---|---|
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2009 |
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2003 |
Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1993 |
49 other studies available for fluorouracil and Liver Cirrhosis
| Article | Year |
|---|---|
Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment.
Topics: Amino Acid Oxidoreductases; Collagen; Collagen Type I; Drug Resistance; Ecosystem; Fluorouracil; Hum | 2022 |
Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Adjuva | 2023 |
A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cell Prolifer | 2017 |
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla | 2013 |
Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2013 |
A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Coloni | 2013 |
Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Fatty Liver; Female; Fluorouracil; Humans; Irin | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Topics: Aged; Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2014 |
Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2014 |
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Gene Expression Regulation, Neopla | 2015 |
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2014 |
Education and Imaging. Hepatobiliary and Pancreatic: Complete remission after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with decompensated cirrhosis.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcino | 2016 |
Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2009 |
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Cisplatin; | 2010 |
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2012 |
[A case of advanced primary colorectal carcinoma accompanied by liver metastasis in which ileus developed due to marked fibrosis with cicatricial formation in primary colorectal cancer treated by chemotherapy including bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2012 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2012 |
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; F | 2003 |
[The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient].
Topics: Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatitis B; Humans; Infusions, Intra-Arteria | 2004 |
Images of interest. Hepatobiliary and pancreatic: Tumor thrombi in esophageal varices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Endoscopy; Eso | 2005 |
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2006 |
[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2006 |
[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2007 |
Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Mon | 2008 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycyti | 2007 |
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1984 |
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1982 |
[Evaluation of chemotherapy in hepatocellular carcinoma with liver cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
Influence of liver dysfunction on dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Leukocytes, Mononucle | 2002 |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Hepat | 2002 |
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop | 1979 |
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined | 1985 |
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv | 1989 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1989 |
Intrahepatic chemotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; | 1988 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec | 1987 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Clinical studies of primary hepatic carcinoma].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Alkaline Phosphatase; Autopsy; Biopsy; Carcinoma, Hepat | 1971 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
Comments on morbidity in present-day radiotherapy.
Topics: Breast Neoplasms; Buttocks; Carcinoma, Squamous Cell; Dactinomycin; Erythema; Female; Fluorouracil; | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |